Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501636 | 0.90 | SCN9A (0.45) | ITKSCN9ALMNAIRAK4SMN1; SMN2 | |
| SCHEMBL6506219 | 0.90 | ITK (0.42) | ITKSMN1; SMN2GRIN2BKDM4EMAPT | |
| SCHEMBL6502246 | 0.88 | ITK (0.44) | ITKLMNAGAAIRAK4GRIN2B | |
| SCHEMBL6497902 | 0.88 | SCN9A (0.43) | ITKSCN9ALMNAIRAK4GRIN2B | |
| SCHEMBL6506096 | 0.87 | SCN9A (0.48) | ITKSCN9ALMNAIRAK4SMN1; SMN2 | |
| SCHEMBL6504059 | 0.86 | ITK (0.45) | ITKSCN9ALMNAGAAIRAK4 | |
| SCHEMBL6505904 | 0.86 | ITK (0.48) | ITKSCN9ALMNAIRAK4SMN1; SMN2 | |
| SCHEMBL6502412 | 0.86 | SCN9A (0.47) | ITKSCN9ALMNAIRAK4SMN1; SMN2 | |
| SCHEMBL6497796 | 0.85 | SCN9A (0.46) | ITKSCN9ALMNAIRAK4SMN1; SMN2 | |
| SCHEMBL6502065 | 0.85 | SCN9A (0.46) | ITKSCN9ALMNAGAAIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | PHARMACIA AND UPJOHN COMPANY LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197338-A1 | Substituted pyrazole urea compounds for the treatment of inflammation | IL4, ARG2, CASP4 | ITK 4236/4885SCN9A 4159/4885LMNA 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.